Health Canada approves Adapt Pharma’s Narcan Nasal Spray

DUBLIN, Ireland — Health Canada on Tuesday approved naloxone hydrochloride nasal spray, a nasal delivery method for the opioid overdose medication, which Adapt Pharma said it would market as Narcan Nasal Spray. 

 

"Adapt Pharma has cooperated with Health Canada throughout the approval process to expedite the approval of the naloxone nasal spray in Canada," Adapt Pharma chairman and CEO Seamus Mulligan, Chairman and Chief Executive Officer of Adapt Pharma. "It is our priority to equip first responders, including the general public, with the ability to potentially treat an opioid overdose, wherever it happens."

 

As Adapt Pharma’s nasal spray awaited Canadian approval, Canada’s health minister signed an interim order allowing for Food and Drug Administration-approved Narcan nasal spray from Adapt to be sold in Canada. Until the Health Canada-approved product launches, the interim order will stay in place, the company said.